Zoledronic acid and clodronate in the treatment of malignant bone metastases with hypercalcaemia; Efficacy and safety comparative study

Medical Oncology

Volumn 28, Issue 2, 2011, Pages 584-590

  Sabry, Nirmeen A ^a,b   Habib, Emad E ^c  

^a CAIRO UNIVERSITY   (Egypt)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c CAIRO UNIVERSITY   (Egypt)

Author keywords

Bone metastases; Cancer; Clodronate; Hypercalcaemia in malignancy; Zoledronic acid

Indexed keywords

CALCIUM; CLODRONIC ACID; ZOLEDRONIC ACID;

ADULT; ANEMIA; ARTICLE; ASTHENIA; BONE METASTASIS; BONE PAIN; CANCER RADIOTHERAPY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; FEMALE; FRACTURE; HEADACHE; HUMAN; HYPERCALCEMIA; HYPOCALCEMIA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SIDE EFFECT; SPINAL CORD COMPRESSION; SPINE FRACTURE; VOMITING;

ADOLESCENT; ADULT; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; CLODRONIC ACID; DIPHOSPHONATES; FEMALE; HUMANS; HYPERCALCEMIA; IMIDAZOLES; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 79960326519     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-010-9461-z     Document Type: Article

References (26)

1. GR Mundy KJ Ibbotson SM D'Souza EL Simpson JW Jacobs TJ Martin 1984 The hypercalcemia of cancer: clinical implications and pathogenic mechanisms N Engl J Med 310 1718 1727 6328302 10.1056/NEJM198406283102607 1:CAS:528: DyaL2cXkslSht7w%3D
2. R Vassilopoulou-Sellin BM Newman SH Taylor VF Guinee 1993 Incidence of hypercalcemia in patients with malignancy referred to a comprehensive cancer center Cancer 71 1309 1312 8382106 10.1002/1097-0142(19930215)71:4<1309::AID- CNCR2820710423>3.0.CO;2-M 1:STN:280:DyaK3s7mvFGrsw%3D%3D (Pubitemid 23054924)
3. J Watters G Gerrand D Dodwell 1996 The management of malignant hypercalcaemia Drugs 52 837 848 8957154 10.2165/00003495-199652060-00005 1:CAS:528:DyaK2sXhsFGl (Pubitemid 26413294)
4. CancerNet. Hypercalcemia (PDQR) Supportive Care-Health Professionals. Available at: http://www.cancer.gov/cancer-information/doc-pdq.aspx?version= provider&viewid=22c0dfeb-f468-4341-8519-27b71bb4686d. Accessed 10 September 2002.
5. M Perazella IM Jibrin GD Lawrence CB Miller 2006 Hypercalcemia of malignancy in hospitalized patients Hosp Physician 42 11 29 35
6. J McMahan T Linneman 2009 A case of resistant hypercalcemia of malignancy with a proposed treatment algorithm Ann Pharmacother 43 9 1532 1538 19622757 10.1345/aph.1L313
7. EJ Small MR Smith JJ Seaman S Petrone MO Kowalski 2003 Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer J Clin Oncol 21 23 4277 4284 14581438 10.1200/JCO.2003.05.147 1:CAS:528:DC%2BD2cXpsVWqu7w%3D (Pubitemid 46621802)
8. K Kawada H Minami K Okabe T Watanabe K Inoue, et al. 2005 Multicenter and open label clinical trial of zoledronic acid 4 mg in patients with hypercalcemia of malignancy Jpn J Clin Oncol 35 1 28 33 15681601 10.1093/jjco/hyi005 (Pubitemid 40450552)
9. RG Russell MJ Rogers JC Frith SP Luckman FP Coxon, et al. 1999 The pharmacology of bisphosphonates and new insights into their mechanisms of action J Bone Miner Res 14 53 65 10510215 10.1359/jbmr.1999.14.11.1828 1:CAS:528:DyaK1MXmsFOis7o%3D (Pubitemid 29521777)
10. N Zojer AV Keck M Pecherstorfer 1999 Comparative tolerability of drug therapies for hypercalcaemia of malignancy Drug Saf 21 389 406 10554053 10.2165/00002018-199921050-00004 1:CAS:528:DyaK1MXnsFWgurw%3D (Pubitemid 29520900)
11. NP O'Rourke EV McCloskey S Vasikaran K Eyres D Fern, et al. 1993 Effective treatment of malignant hypercalcaemia with a single intravenous infusion of clodronate Br J Cancer 67 560 563 8439504 10.1038/bjc.1993.102 (Pubitemid 23077652)
12. L Widler KA Jaeggi M Glatt K Müller R Bachmann, et al. 2002 From pamidronate disodium (Aredia) to zoledronic acid (Zometa) J Med Chem 45 3721 3738 12166945 10.1021/jm020819i 1:CAS:528:DC%2BD38Xltl2jtLw%3D (Pubitemid 34863233)
13. HL Neville-Webbe RE Coleman 2003 The use of zoledronic acid in the management of metastatic bone disease and hypercalcaemia Palliat Med 17 6 539 553 14526888 10.1191/0269216303pm800ra 1:STN:280:DC%2BD3svmsVOmsQ%3D%3D (Pubitemid 37160894)
14. JR Berenson LS Rosen A Howell L Porter RE Coleman, et al. 2001 Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases Cancer 91 1191 1200 11283917 10.1002/1097-0142(20010401)91:7<1191::AID- CNCR1119>3.0.CO;2-0 1:CAS:528:DC%2BD3MXislyhtLg%3D (Pubitemid 32267028)
15. Declaration of Helsinki-Current (2008) version. Available at http://www.wma.net/e/policy/pdf/17c.pdf. Accessed August 2009.
16. Guideline for Good Clinical Practice. European Medicines Agency, CPMP/ICH/135/95, July 2002. Available at: http://www.emea.europa.eu/pdfs/human/ ich/013595en.pdf. Accessed August 2008.
17. Fleisch H. Bisphosphonates: a new class of drugs in diseases of bone and calcium metabolism. Berlin: Springer; 1989.
18. GA Rodan HA Fleisch 1996 Bisphosphonates: mechanism of action J Clin Invest 97 2692 2696 8675678 10.1172/JCI118722 1:CAS:528:DyaK28XjvVWksrw%3D
19. SD Averbuch 1993 New bisphosphonates in the treatment of bone metastases Cancer 72 3443 3452 8242577 10.1002/1097-0142(19931201)72:11+<3443::AID- CNCR2820721611>3.0.CO;2-3 1:STN:280:DyaK2c%2FmtFOruw%3D%3D (Pubitemid 23357988)
20. GR Munoy 2002 Bisphosphosnates and tumor burden J Clin Oncol 20 3191 3192
21. P Major A Lortholary J Hon E Abdi G Mills, et al. 2001 Zoledronic acid is superior to pamidronate in the treatment of hypercalcaemia of malignancy: a pooled analysis of two randomized, controlled clinical trials J Clin Oncol 19 558 567 11208851 1:CAS:528:DC%2BD3MXhtVektLk%3D (Pubitemid 32112871)
22. ST Atula RK Tähtelä JI Nevalainen LH Pylkkänen 2003 Clodronate as a single-dose intravenous infusion effectively provides short-term correction of malignant hypercalcemia Acta Oncol 42 6 735 740 14690159 10.1080/02841860310013111 1:CAS:528:DC%2BD3sXpvFyrsL8%3D (Pubitemid 37445293)
23. RJ Cook P Major 2001 Methodology for treatment evaluation in patients with cancer metastatic to bone J Natl Cancer Inst 93 534 538 11287447 10.1093/jnci/93.7.534 1:STN:280:DC%2BD3M3gtVCqug%3D%3D (Pubitemid 32318432)
24. M Saber T Shouman 2003 Clodronate therapy in patients with breast cancer and bone metastases J Egypt Nat Cancer Inst 15 3 209 215
25. S Houston R Rubens 1998 The tolerability and adverse event profile of pamidronate disodium Rev Contemp Pharmacother 9 213 224 1:CAS:528: DyaK1cXlsVeqtL8%3D (Pubitemid 28369702)
26. A Ibrahim N Scher G Williams R Sridhara N Li, et al. 2003 Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases Clin Cancer Res 9 2394 2399 12855610 1:CAS:528:DC%2BD3sXlt1ykur4%3D (Pubitemid 36842077)